MarketPeel
Insider Trading Intelligence
CR

Chandler Robinson

MNPR
CHIEF EXECUTIVE OFFICER · MONOPAR THERAPEUTICS · CIK 0001727334
FILING MIX · LIFETIME40%/60%
BUYS
41
SELLS
62
TOTAL VALUE
$40.03M
COMPANIES
1
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
93,403
AVG SELL PX
$48.42
TRADE KIND
SHOWING 103 / 103
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
8 backtested trades · 8 horizons · 5 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Chandler Robinson, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d8+75.00%-12.12%-0.13%-11.98%-20.76%
14d8+87.50%-14.82%-1.73%-13.09%-28.14%
30d8+75.00%-17.06%+1.29%-18.36%-29.16%
60d8+75.00%-29.96%+4.98%-34.94%-57.12%
90d8+87.50%-17.45%+5.01%-22.46%-55.42%
180d8+75.00%-18.32%+12.25%-30.57%-66.97%
1y8(2 pending)+83.33%-52.96%+14.56%-67.52%-86.41%
2y8(3 pending)+100.00%-65.19%+7.55%-72.74%-72.74%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
MNPR · 93,403 shares · as of Jun 30, 2026
0205,564411,128616,691822,255202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 41 buys / 62 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
4,084$92.59$378.1K99,267Jun 30, 2026Jul 2, 2026View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
12,87393,403Jun 30, 2026Jul 2, 2026View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
12,873103,351Jun 30, 2026Jul 2, 2026View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
6,732106,276Mar 31, 2026Apr 2, 2026View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
1,972$54.79$108.0K90,478Mar 31, 2026Apr 2, 2026View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
6,73292,450Mar 31, 2026Apr 2, 2026View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
8,72488,276Dec 31, 2025Jan 5, 2026View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
8,724113,008Dec 31, 2025Jan 5, 2026View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
2,558$65.30$167.0K85,718Dec 31, 2025Jan 5, 2026View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
16,75316,753Dec 2, 2025Dec 8, 2025View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
49,133121,732Dec 2, 2025Dec 8, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
2,646$81.67$216.1K79,552Sep 30, 2025Oct 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
8,72682,198Sep 30, 2025Oct 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
8,72672,599Sep 30, 2025Oct 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
550,229$63.61$35.00M272,026Sep 24, 2025Sep 26, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
16,8000Jul 14, 2025Jul 16, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
16,800$40.00$672.0K73,472Jul 14, 2025Jul 16, 2025View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
16,800$0.01$8490,272Jul 14, 2025Jul 16, 2025View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
13,34479,337Jun 30, 2025Jul 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
13,34481,325Jun 30, 2025Jul 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
5,865$35.78$209.8K73,472Jun 30, 2025Jul 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
33,334$35.00$1.17M822,255Apr 2, 2025Apr 4, 2025View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
4,10667,197Mar 31, 2025Apr 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
1,204$36.41$43.8K65,993Mar 31, 2025Apr 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
4,10694,669Mar 31, 2025Apr 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
1,759$31.70$55.8K63,091Mar 4, 2025Mar 7, 2025View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
79,899104,777Mar 4, 2025Mar 7, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
6,00298,775Mar 4, 2025Mar 7, 2025View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
85,75985,759Mar 4, 2025Mar 7, 2025View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
6,00264,850Mar 4, 2025Mar 7, 2025View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
62,81562,815Jan 28, 2025Jan 30, 2026View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
4,89524,879Dec 31, 2024Jan 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
4,89561,057Dec 31, 2024Jan 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
2,209$22.00$48.6K58,848Dec 31, 2024Jan 2, 2025View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
1,918$6.74$12.9K56,162Sep 30, 2024Oct 2, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
4,89529,774Sep 30, 2024Oct 2, 2024View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
4,89558,080Sep 30, 2024Oct 2, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
8,684$0.73$6.3K265,922.8Jun 30, 2024Jul 2, 2024View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
24,476274,606.8Jun 30, 2024Jul 2, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
24,476173,335Jun 30, 2024Jul 2, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
84,0000May 28, 2024May 30, 2024View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
84,000$0.00$84250,130.8May 28, 2024May 30, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
24,474197,811Mar 31, 2024Apr 2, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
7,172$0.68$4.9K166,130.8Mar 31, 2024Apr 2, 2024View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
24,474173,302.8Mar 31, 2024Apr 2, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
2,327$0.34$792148,828.8Jan 1, 2024Jan 3, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
6,724222,285Jan 1, 2024Jan 3, 2024View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
6,724151,155.8Jan 1, 2024Jan 3, 2024View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
24,474152,900.8Dec 31, 2023Jan 3, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
24,474229,009Dec 31, 2023Jan 3, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
8,469$0.34$2.9K144,431.8Dec 31, 2023Jan 3, 2024View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
24,474253,483Sep 30, 2023Oct 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
7,172$0.62$4.4K128,426.8Sep 30, 2023Oct 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
24,474135,598.8Sep 30, 2023Oct 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
10,269$0.86$8.8K111,124.8Jun 30, 2023Jul 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
35,039277,957Jun 30, 2023Jul 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
35,039121,393.8Jun 30, 2023Jul 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
13,91190,640.8Mar 31, 2023Apr 4, 2023View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
4,286$1.39$6.0K86,354.8Mar 31, 2023Apr 4, 2023View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
13,911312,996Mar 31, 2023Apr 4, 2023View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
169,012326,907Feb 1, 2023Feb 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
221,839221,839Feb 1, 2023Feb 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
2,327$2.37$5.5K76,729.8Jan 1, 2023Jan 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
6,72379,056.8Jan 1, 2023Jan 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
6,7236,724Jan 1, 2023Jan 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
13,912151,171Dec 31, 2022Jan 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
4,814$2.37$11.4K72,333.8Dec 31, 2022Jan 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
13,91277,147.8Dec 31, 2022Jan 3, 2023View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
13,91167,312.8Sep 30, 2022Oct 3, 2022View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
4,077$1.52$6.2K63,235.8Sep 30, 2022Oct 3, 2022View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
13,911178,530Sep 30, 2022Oct 3, 2022View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
23,88260,400.8Jun 30, 2022Jul 1, 2022View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
6,999$2.30$16.1K53,401.8Jun 30, 2022Jul 1, 2022View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
23,882192,441Jun 30, 2022Jul 1, 2022View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
3,941216,323Mar 31, 2022Apr 1, 2022View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
1,155$2.55$2.9K36,518.8Mar 31, 2022Apr 1, 2022View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
3,94137,673.8Mar 31, 2022Apr 1, 2022View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
211,018211,018Feb 2, 2022Feb 4, 2022View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
159,522220,264Feb 2, 2022Feb 4, 2022View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
2,327$3.21$7.5K33,732.8Jan 1, 2022Jan 4, 2022View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
6,72413,447Jan 1, 2022Jan 4, 2022View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
6,72436,059.8Jan 1, 2022Jan 4, 2022View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
3,94130,699.8Dec 31, 2021Jan 4, 2022View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
3,94147,295Dec 31, 2021Jan 4, 2022View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
1,364$3.21$4.4K29,335.8Dec 31, 2021Jan 4, 2022View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
3,94127,913.8Sep 30, 2021Oct 1, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
3,94151,236Sep 30, 2021Oct 1, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
1,155$4.87$5.6K26,758.8Sep 30, 2021Oct 1, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
7,88355,177Jun 30, 2021Jul 2, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
2,310$5.89$13.6K23,972.8Jun 30, 2021Jul 2, 2021View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
7,88326,282.8Jun 30, 2021Jul 2, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
24,224$14.09$341.3K224,976Feb 11, 2021Feb 16, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
16,384$16.44$269.4K178,596Feb 11, 2021Feb 16, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
42,467$13.30$564.8K249,200Feb 11, 2021Feb 16, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
11,929$16.90$201.6K166,667Feb 11, 2021Feb 16, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
29,996$15.12$453.5K194,980Feb 11, 2021Feb 16, 2021View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
70,00070,000Jan 26, 2021Jan 28, 2021View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
63,06083,231Jan 26, 2021Jan 28, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
2,327$6.12$14.2K18,399.8Jan 1, 2021Jan 5, 2021View →
MNPR
MONOPAR THERAPEUTICS
PURCHASE
Chief Executive Officer
6,72420,726.8Jan 1, 2021Jan 5, 2021View →
MNPR
MONOPAR THERAPEUTICS
SALE
Chief Executive Officer
6,72420,171Jan 1, 2021Jan 5, 2021View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
111,753111,753Jan 31, 2020Feb 20, 2020View →
MNPR
MONOPAR THERAPEUTICS
PURCHASEGRANT
Stock grant
26,89526,895Jan 31, 2020Feb 20, 2020View →
Other insiders · MNPR
Loading peer insiders…
About this filer
CIK 0001727334
ROLE
Chief Executive Officer
PRIMARY
MNPR
COMPANIES
1
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001727334DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback